Search results for "PD"

showing 10 items of 1971 documents

A year in the life of German patients with COPD: the DACCORD observational study

2016

Roland Buhl,1 Carl-Peter Criée,2 Peter Kardos,3 Claus Vogelmeier,4,5 Nadine Lossi,6 Claudia Mailänder,6 Heinrich Worth7 1Pulmonary Department, Mainz University Hospital, Mainz, 2Department of Sleep and Respiratory Medicine, Evangelical Hospital Göttingen-Weende, Bovenden, 3Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, 4Department of Medicine, Pulmonary, and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, 5German Center for Lung Research, Marburg, 6Clinical Research Primary Care, Novartis Pharma GmbH, Nürnberg, 7Facharztforum F&…

Malemedicine.medical_specialtyPediatricsTime FactorsPulmonary diseaseDiseaseInternational Journal of Chronic Obstructive Pulmonary DiseaseSeverity of Illness IndexSecondary CareSecondary careGerman03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineAmbulatory careRisk FactorsForced Expiratory VolumeGermanyEpidemiologymedicineCOPDHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesLungOriginal ResearchAgedCOPDPrimary Health Carebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaselanguage.human_languageBronchodilator AgentsTreatment Outcome030228 respiratory systemCOPD exacerbationsSpirometryEmergency medicinelanguageDisease ProgressionObservational studyepidemiologybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Contrast enhanced CT-scans are not comparable to non-enhanced scans in emphysema quantification.

2010

Systemic, interventional and surgical treatments have gone new ways in treatment of emphysema. For longitudinal therapy monitoring and as end-points for clinical trials, quantification of the disease is necessary. Sensitive, easy to measure, as well as stable and reproducible parameters have to be characterized. One parameter that might affect emphysema quantification is IV contrast enhancement, which might also be indicated. Whether or not the contrast enhanced scan is also suited for emphysema quantification or an additional scan is necessary, a retrospective analysis of 12 adult patients undergoing clinically indicated both, a non-enhanced and enhanced thin section MSCT within a week (me…

Malemedicine.medical_specialtyPercentilemedia_common.quotation_subjectContrast MediaSensitivity and SpecificityIopamidolParenchymaContrast (vision)MedicineHumansRadiology Nuclear Medicine and imagingLung volumesmedia_commonEmphysemaCOPDLungbusiness.industryRespiratory diseaseReproducibility of ResultsGeneral Medicinerespiratory systemMiddle Agedmedicine.diseaserespiratory tract diseasesIopamidolmedicine.anatomical_structureFemaleRadiologybusinessTomography X-Ray Computedmedicine.drugEuropean journal of radiology
researchProduct

Relaxant effect of sildenafil in the rabbit basilar artery

2005

We hypothesized that sildenafil, inhibitor of phosphodiesterase-5 (PDE-5), interacts with the nitric oxide (NO)-cGMP pathway in the cerebral arteries and shows vasoactive effects. To prove it in the isolated rabbit basilar artery, we compared the effects of sildenafil with other PDE-5 inhibitors, assessed the endothelial dependence of the vasoactive responses, and used modulators of the cGMP and cAMP signaling processes. Sildenafil (10 nM-0.1 mM) induced concentration-dependent relaxations of endothelin-1 (10 nM)-precontracted basilar artery, which were partially inhibited both in endothelium-denuded arteries and in arteries precontracted by depolarization with KCl (50 mM). Endothelin-1 (1 …

Malemedicine.medical_specialtyPhosphodiesterase InhibitorsPhysiologySildenafilVasodilator AgentsCerebral arteriesVasodilationIn Vitro TechniquesPiperazinesSildenafil Citratechemistry.chemical_compound3'5'-Cyclic-GMP PhosphodiesterasesQuinoxalinesmedicine.arteryInternal medicinemedicineBasilar arteryAnimalsSulfonesCyclic Nucleotide Phosphodiesterases Type 5PharmacologyOxadiazolesDose-Response Relationship DrugPhosphoric Diester HydrolasesPDE5 drug designVasodilationNG-Nitroarginine Methyl EsterEndocrinologychemistryGuanylate CyclasePurinesBasilar Arterycardiovascular systemMolecular MedicineRabbitsSodium nitroprussideNitric Oxide SynthaseSoluble guanylyl cyclaseZaprinastSignal Transductionmedicine.drugVascular Pharmacology
researchProduct

GOLD and the fixed ratio

2012

We thank Dr Vestbo for his interest in our manuscript “Diagnosis of airway obstruction in the elderly: contribution of the SARA study” and for the opportunity to clarify some points. As mentioned in the title and aims, the intent of the paper is to offer a contribution to the open issue of identification of airway obstruction in elderly people.1 We agree with Dr Vestbo about the utility of distinguishing between the clinical and functional aspects of chronic obstructive pulmonary disease (COPD). We stress that, until the term COPD is used, diagnosis needs clinical evidence of a chronic pulmonary disease and functional evidence of airway obstruction. Given that symptoms compatible with COPD …

Malemedicine.medical_specialtyPopulationspirometryDiseaseInternational Journal of Chronic Obstructive Pulmonary Diseaseairflow obstructionchronic obstructive pulmonary diseaseFEV1/FVC ratioPulmonary Disease Chronic ObstructiveEpidemiologymedicineHumansOverdiagnosisMedical prescriptionIntensive care medicineeducationOriginal Researchlcsh:RC705-779COPDeducation.field_of_studybusiness.industryagingGeneral Medicinelung function testslcsh:Diseases of the respiratory systemAirway obstructionrespiratory systemmedicine.diseaseforced expiratory volumerespiratory tract diseasesPhysical therapyFemalebusinesscirculatory and respiratory physiologyInternational Journal of COPD
researchProduct

COPD significantly increases cerebral and cardiovascular events in hypertensives

2021

AbstractEssential hypertension and chronic obstructive pulmonary disease often coexist in the same patient. The aim of this study was to evaluate whether the addition of chronic obstructive pulmonary disease modifies the risk of cardiovascular events in hypertensives. We enrolled 1728 hypertensives. Study outcomes included fatal and non-fatal cardiovascular stroke and myocardial infarction, and cardiovascular death. During a mean follow-up of 57 months there were 205 major adverse cardiovascular events (2.47 per 100 pts/yr): cardiac (n117; 1.41 per 100 pts/yr) and cerebrovascular (n = 77; 0.93 per 100 pts/yr). In hypertensives with chronic obstructive pulmonary disease we observed a greater…

Malemedicine.medical_specialtyScienceCardiologyPulmonary disease030204 cardiovascular system & hematologyEssential hypertensionArticleCardiovascular deathPulmonary Disease Chronic Obstructive03 medical and health sciencesMedical research0302 clinical medicineInternal medicinemedicineHumansMyocardial infarctionStrokeAgedessential hypertension; chronic obstructive; pulmonary diseaseCOPDMultidisciplinarybusiness.industryIncidenceIncidence (epidemiology)QRespiratory diseaseRMiddle Agedmedicine.diseaseRisk factors030228 respiratory systemHypertensionCardiologyMedicineFemaleCOPD Hypertensionbusiness
researchProduct

Right ventricular diameter predicts all-cause mortality in heart failure with preserved ejection fraction.

2019

Left ventricular ejection fraction (EF) is helpful to differentiate heart failure (HF) phenotype in clinical practice. The aim of the study was to identify simple echocardiographic predictors of post-discharge all-cause mortality in hospitalized HF patients. Patients with acute HF (75 ± 9.8 years), classified in preserved (≥ 50%) and reduced (< 50%) EF (HFpEF and HFrEF, respectively), were enrolled. The mean follow-up period was of 25.4 months. Patients definitively analyzed were 135. At multivariate Cox model, right ventricular diameter (RVd), inferior vena cava diameter (IVCd) and blood urea nitrogen (BUN) resulted to be significantly associated with all-cause mortality in HFpEF (HR 2.…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaHeart Ventricles030204 cardiovascular system & hematologyInferior vena cava03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineInternal MedicineMedicineHumans030212 general & internal medicineBlood urea nitrogenAgedAged 80 and overHeart FailureCOPDEjection fractionbusiness.industryProportional hazards modelheart failure echocardiography mortalityStroke VolumeMiddle AgedWeights and Measuresmedicine.diseasePrognosismedicine.veinItalyEchocardiographyHeart failureEmergency MedicineCardiologyFemalebusinessHeart failure with preserved ejection fractionAll cause mortalityInternal and emergency medicine
researchProduct

Response to ‘The trap door flap: A reliable, reproducible method of anterior pinna reconstruction’

2013

Malemedicine.medical_specialtySkin Neoplasmsbiologybusiness.industryPinnaSettore MED/19 - Chirurgia PlasticaTrap doorAnatomyPlastic Surgery Proceduresbiology.organism_classificationSurgical FlapsSurgeryretroauricular flapsHumansMedicineFemaleSurgeryEar ExternalbusinessEar reconstructiontrapdoor flapJournal of Plastic, Reconstructive & Aesthetic Surgery
researchProduct

Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect?

2019

Urinary incontinence (UI) is defined as a loss of bladder control and is characterized by the complaint of any involuntary leakage of urine. Evidence suggests that the prevalence of UI is higher in subjects with chronic obstructive pulmonary disease (COPD) than in age-matched controls in both sexes. UI is classified as stress, urge, and mixed, and has a considerable impact on quality of life. However, the prevalence of UI in individuals with COPD is mostly unexplored in clinical research and often underestimated in clinical practice. Interestingly, although the involuntary leakage of a small amount of urine during coughing (e.g., stress UI) is among the most plausible causes of UI in patien…

Malemedicine.medical_specialtyUrinary incontinenceAnticholinergic agentsComorbidity03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesPrevalenceMedicineHumansCOPDPharmacology (medical)030212 general & internal medicineAdverse effectbladderAgedCOPDbusiness.industryUrinary retentionmedicine.diseaseComorbidityClinical researchUrinary IncontinenceQuality of LifeFemaleGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

2016

Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Pulmonary Specialist Practice, Wiesbaden, Germany; 5Biometrics, Alcedis GmbH, Gießen, Germany Background: Maintaining and improving physical functioning is key to mitigating the cycle of deconditioning associated with chronic obstructive pulmonary disease (COPD). We evaluated the impact of free combination of the long-acting anticholinergic tiotropium plus the long-acting β2-agonist ol…

Malereal-worldTime FactorsnoninterventionalHealth StatusSeverity of Illness IndexCholinergic AntagonistsPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicinetiotropiumDeconditioningPhysical functioningSurveys and QuestionnairesProspective Studies030212 general & internal medicineLungOriginal ResearchCOPDOlodaterolGeneral MedicineTiotropium bromideMiddle AgedBronchodilator AgentsDrug CombinationsTreatment OutcomeFemalemedicine.drugmedicine.medical_specialtymedicine.drug_classInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive pulmonary disease03 medical and health sciencesAdministration InhalationSeverity of illnessmedicineAnticholinergicphysical functioningHumansTiotropium BromideIntensive care medicineAdrenergic beta-2 Receptor AgonistsAgedolodaterolbusiness.industryNebulizers and VaporizersRecovery of Functionmedicine.diseaseBenzoxazines030228 respiratory systemchemistryPhysical therapyObservational studybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

2014

Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained con…

Malevirus strainResistanceHIV InfectionsDrug resistanceTHERAPYNucleoside Reverse Transcriptase InhibitorANTIRETROVIRAL DRUG-RESISTANCE0302 clinical medicineMedical microbiologyGenotypeMedicine and Health SciencesPrevalenceHIV Infection030212 general & internal medicineUNITED-KINGDOMPhylogeny0303 health sciencesCommunicable diseaseTransmission (medicine)adultvirus mutationUPDATED RECOMMENDATIONSvirus transmission3. Good healthEuropeInfectious Diseasesfemalerisk factorvirus resistanceFemaleNAIVE PATIENTSSOCIETY-USA PANELResearch ArticleHumanAdultmedicine.medical_specialtyGenotypeAnti-HIV AgentsVirusArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingmaleMOLECULAR EPIDEMIOLOGYDrug Resistance Viralmedicineproteinase inhibitorHumansTransmissioncontrolled studyhumanmolecular phylogeny030304 developmental biologynonhumanMUTATIONSbusiness.industryAnti-HIV Agentnucleotide sequencenonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequenceParasitology3121 General medicine internal medicine and other clinical medicineMutationHIV-1business
researchProduct